title: Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
abstract: The heterogeneous biology of glioblastoma (GBM) emphasizes the need for imaging methods to assess tumor burden and assist in evaluating individual patients. The purpose of this study was to investigate early changes in metrics from 3D 1H magnetic resonance spectroscopic imaging (MRSI) data, compare them with anatomic lesion volumes, and determine whether they were associated with survival for patients with newly diagnosed GBM receiving a multimodality treatment regimen.
  
  
  
  Serial MRI and MRSI scans provided estimates of anatomic lesion volumes and levels of choline, creatine, N-acetylaspartate, lactate, and lipid. The association of metrics derived from these data with survival was assessed using Cox proportional hazards models with adjustments for age, Karnofsky performance score, and extent of resection. Temporal changes in parameters were evaluated using a Wilcoxon signed rank test.
  
  
  
  Anatomic lesion volumes at the post-radiotherapy (RT) scan, metabolic lesion volume at mid-RT and post-RT scans, as well as metrics describing levels of choline, lactate, and lipid were associated with overall survival. There was a significant reduction in the enhancing lesion volume, increase in T2 lesion volume from mid-RT to post-RT, and decrease in parameters describing metabolite levels during these early time points.
  
  
  
  The MRSI data provided metrics that described the effects of treatment on the metabolic lesion burden and were associated with overall survival. This suggests that adding these parameters to standard assessments of changes in anatomic lesion volumes could contribute to making early decisions about the efficacy of such combination therapies.
authors: Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
authors: Sarah J
authors: SJ
authors: Nelson
authors: Surbeck Laboratory of Advanced Imaging, University of California, San Francisco, California.
authors: Achuta K
authors: AK
authors: Kadambi
authors: Surbeck Laboratory of Advanced Imaging, University of California, San Francisco, California.
authors: Ilwoo
authors: I
authors: Park
authors: Surbeck Laboratory of Advanced Imaging, University of California, San Francisco, California.
authors: Yan
authors: Y
authors: Li
authors: Surbeck Laboratory of Advanced Imaging, University of California, San Francisco, California.
authors: Jason
authors: J
authors: Crane
authors: Surbeck Laboratory of Advanced Imaging, University of California, San Francisco, California.
authors: Marram
authors: M
authors: Olson
authors: Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.|Department of Neurological Surgery, University of California, San Francisco, California.
authors: Annette
authors: A
authors: Molinaro
authors: Surbeck Laboratory of Advanced Imaging, University of California, San Francisco, California.
authors: Ritu
authors: R
authors: Roy
authors: Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.|Department of Neurological Surgery, University of California, San Francisco, California.
authors: Nicholas
authors: N
authors: Butowski
authors: Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.|Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.|Department of Neurological Surgery, University of California, San Francisco, California.
authors: Soonmee
authors: S
authors: Cha
authors: Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
authors: Susan
authors: S
authors: Chang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D002794:Choline / Q000378:metabolism; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003401:Creatine / Q000378:metabolism; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000378:metabolism / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000379:methods; D007211:Indoles / Q000008:administration & dosage; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011379:Prognosis; D020266:Radiotherapy, Conformal; D015996:Survival Rate; D000077204:Temozolomide; D047368:Tumor Burden
chemical_list: D007211:Indoles; D003606:Dacarbazine; D003401:Creatine; D002794:Choline; C504878:enzastaurin; D000077204:Temozolomide
keywords: 1H MR spectroscopic imaging; metabolic parameters; newly diagnosed GBM; predicting outcome; survival; treatment